Background and objective: Migraine is a primary headache disorder that puts a huge burden on patients normal functioning and productivity because of its abundant prevalence and young age of onset. Hence any drug study on migraine should necessarily evaluate the drug’s efficacy in improving patients Quality Of Life (QOL) apart from reducing migraine frequency. We previously reported that memantine 10 mg per day produced a statistically significant reduction in mean monthly migraine headache days. To define yet more clearly the utility of memantine in the treatment of migraine, we evaluated secondary endpoints namely QOL from the trial. Methods: It was a randomized, placebo controlled double blind study including adult patients with 3–12 migraine headaches for last six months. Patients received memantine (10mg/day, once a day) or placebo for the period of 24 weeks after a wash out period. Along with Migraine frequency per month, the 50% responder rate, rescue medication use and adverse events, mean MIDAS (Migraine Disability Assessment) score was recorded every 4 weeks. Results: The mean MIDAS score for memantine receiving patients was; at baseline; 12.00 (±1.04) vs. at week 24; 3.64 (±0.42) and placebo receiving patients was at baseline; 12.55 (±0.89) vs. week 24; 7.76 (±0.66). The MIDAS score by week 24 was significantly less (p=0.0001) in patients receiving memantine than that of placebo receiving patients Conclusions: In addition to significantly reducing mean monthly migraine headache days, treatment of migraine with memantine was indeed effective with regard to clinically relevant Quality of life measures.